Did the post-COVID-19 era change the health priorities of global consumers of dietary supplements? What about mood & brain health, and cognitive functions?
A recent IPSOS study ranks mental health as the biggest health concern, after Covid-19 and cancer. Mental health includes mood status, cognitive health as well as the ability to think, learn and remember. In this dynamic context, the demand for cognitive support supplementation is growing steadily, with a global brain health supplement market accounting for $8 billion in 2021, and a promising compound annual growth rate (CAGR) of 9% expected from 2021-2028.
A new White Paper just issued on Adonat Premium SAMe (S-adenosyl-methionine), the proprietary brand of Gnosis by Lesaffre, offers a wide range of opportunities to sustain the body’s well-being, brain health, and cognitive functions and to answer to new priorities in consumer needs and concerns. Through the identification of the new market scenarios and the major market trends, the White Paper offers a wide overview of the mechanisms and actions of this important human methylator, essential for cells’ life and the whole human health.
The White paper covers clinical data, and applications either on the consolidated field – mood, cognitive, liver, joint, and longevity – and more new ones, especially in the emerging Brain health sector – epigenetics, stress and anxiety, attention, concentration, motor-cortex function.